FDA advisers vote against Capricor's Duchenne heart disease therapy
CAPR•FDA panel votes against deramiocel
July 29 (Reuters) - The U.S. FDA's panel of independent advisers on Wednesday voted against the benefits of Capricor Therapeutics' CAPR.O cell therapy, deramiocel, for treating cardiomyopathy in Duchenne muscular dystrophy, a rare muscle-wasting disease.
